EAU 2026
EAU 2026
Prostate Cancer Symposium:
Our satellite symposium brings together a distinguished multidisciplinary panel to evaluate current evidence and its impact on evolving prostate cancer care. Through case-based discussions, the panel fosters harmonised clinical decision-making across the diverse EMEA region.
Diversity in GU Session:
An international panel explores evidence-based strategies to enhance gender and broader diversity representation in clinical leadership worldwide.
13-16 March 2026 | London, UK
About the Prostate Cancer Session
Navigating metastatic prostate cancer: A multidisciplinary perspective
A multidisciplinary faculty discussion critically appraising current evidence, personalising mHSPC treatment, and addressing risk factors to harmonise evolving prostate cancer care across EMEA.
Key topics covered
- To critically appraise and integrate current evidence and the impact on evolving standards of care in prostate cancer, leveraging multidisciplinary, case-based discussions to harmonize clinical decision-making across the diverse EMEA region
- Review current evidence for the treatment of mHSPC, including how clinical and biological factor scan inform treatment personalisation
- Consider the risk factors associated with poorer outcomes in metastatic prostate cancer
Hear from the Experts
Prof. Alison Birtle
Prof. Birtle highlights the need for holistic patient assessment and responsive treatment strategies in mHSPC based on consistent trial results, along with unanswered questions around PSA‑driven decisions.
Prof. Marc-Olivier Timsit
Prof. Timsit discusses how multidisciplinary collaboration, genetic testing, trial interpretation and treatment selection can shape modern management of metastatic prostate cancer.
Prof. Gunhild von Amsberg
Prof. von Amsberg highlights the importance of aligning mHSPC treatment choices with individual patient goals, quality of life, and clinical factors.
Prof. Dr. Sofie Verbeke
Prof. Verbeke outlines patient considerations and timing of BRCA testing, and how evolving molecular and digital pathology can improve personalised prostate cancer care.
Featured Prostate Cancer Events
Join our upcoming symposia and webinars hosted by our leading specialists. Registration for events and access to post-event recordings and materials are available exclusively for J&J Medical Cloud users.
12-16 September 2026
ECP 2026
Stockholm, Sweden
We're excited to host a GU medical education industry satellite symposium at ECP 2026. Join us in Stockholm for engaging discussions and expert insights in GU oncology.
23-27 October 2026
Join us at ESMO 2026 as we look forward to sharing insights and engaging in meaningful medical education - details to come
ESMO 2026
Madrid, Spain
Join us at ESMO 2026 as we look forward to sharing insights and engaging in meaningful medical education - details to come
5-8 November 2026
EMUC 2026
Brussels, Belgium
We look forward to EMUC 2026, where we will deliver a dedicated prostate cancer medical education symposium, with insights and full programme details coming soon
Register or sign in for J&J Medical Cloud to unlock access to upcoming events, stay updated on the latest educational opportunities, and connect with a network of healthcare professionals.
Past Events
If you registered for a previous session but were unable to attend, you can log in to access recorded sessions and request materials. Please note that for some recordings and materials, the content may not be available in your country.
How is precision medicine reshaping prostate cancer management?
How is precision medicine reshaping prostate cancer management?
Best practice in precision medicine for prostate cancer - filmed at ESMO 2025
Dr. Elena Castro, Dr. Pasquale Rescigno, Prof. Gert Attard and Prof. Axel Heidenreich discuss how personalised approaches, genomic testing, and targeted therapies are transforming prostate cancer care and improving patient outcomes.
What is the value of earlier testing in metastatic prostate cancer?
What is the value of earlier testing in metastatic prostate cancer?
The importance of early testing in metastatic prostate cancer (mPC) – filmed at ASCO 2025
Prof. Eleni Efstathiou, Prof. Gert Attard, Dr. Elena Castro, and Dr. Brigida Maiorano examine the latest trials and discuss the need for earlier testing in mPC to aid treatment decisions.
What new mechanisms of action are coming to the prostate cancer space?
What new mechanisms of action are coming to the prostate cancer space?
New mechanisms of action in prostate cancer treatment – filmed at ASCO 2025
Dr. Joaquin Mateo, Dr. Andrew Parsonson, and Dr. Capucine Baldini discuss promising mechanisms of action in the prostate cancer space, including antibody-drug conjugates, bispecific antibodies, and combination therapies.
Register with J&J Medical Cloud to access our full education library, including recordings, slides, and new session announcements.
Stay in Touch
Contact us
To report an Adverse Event (medication side-effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
BRCA, breast cancer gene; GU, genitourinary; mHSPC, metastatic hormone-sensitive prostate cancer; mPC, metastatic prostate cancer; PSA, prostate-specific antigen.CP-566368 - April 2026
